Clinical Trial

KSH01-TCRT Solid Tumors

Study acronym: KSH01-TCRT
Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 3, 2023 (before its estimated July 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
1\) Safety and efficacy of TCR-T cells in subjects with refractory/relapsed solid tumors. 2) The activation and proliferation of TCR-T cells in the subject, and the survival time.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-09-12; most recent amendment 2023-03-31.
Trial Details
NCT Number NCT05539833
Lead Sponsor TCRx Therapeutics Co.Ltd
Conditions TCR-T Cells, Refractory Solid Tumors, Relapsed Solid Tumors
Enrollment 50 participants
Start Date 2022-08-19
Primary Completion 2025-07-31 (estimated)
Study Completion 2027-07-31 (estimated)
Updated on ClinicalTrials.gov 2023-04-03